Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KTTA
Upturn stock ratingUpturn stock rating

Pasithea Therapeutics Corp (KTTA)

Upturn stock ratingUpturn stock rating
$0.72
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: KTTA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $2

1 Year Target Price $2

Analysts Price Target For last 52 week
$2Target price
Low$0.7
Current$0.72
high$7.5

Analysis of Past Performance

Type Stock
Historic Profit -51.68%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.65M USD
Price to earnings Ratio -
1Y Target Price 2
Price to earnings Ratio -
1Y Target Price 2
Volume (30-day avg) 1
Beta 0.34
52 Weeks Range 0.70 - 7.50
Updated Date 06/30/2025
52 Weeks Range 0.70 - 7.50
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -10.6

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -46.84%
Return on Equity (TTM) -82.81%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -6326684
Price to Sales(TTM) 42.15
Enterprise Value -6326684
Price to Sales(TTM) 42.15
Enterprise Value to Revenue 277.44
Enterprise Value to EBITDA 2.9
Shares Outstanding 7443580
Shares Floating 6931236
Shares Outstanding 7443580
Shares Floating 6931236
Percent Insiders 3.27
Percent Institutions 13.22

Analyst Ratings

Rating 1
Target Price 2
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Pasithea Therapeutics Corp

stock logo

Company Overview

overview logo History and Background

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. The company was founded in 2019.

business area logo Core Business Areas

  • CNS Therapeutics Development: Focuses on developing novel treatments for psychiatric and neurological disorders, utilizing psychedelic-based therapies and other innovative approaches. Currently focusing on NET-100A, a PAS agonist.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in the pharmaceutical and biotechnology industries. The organizational structure includes research and development, clinical operations, and business development functions.

Top Products and Market Share

overview logo Key Offerings

  • NET-100A: A PAS agonist being developed for the treatment of Multiple Sclerosis and potentially other neurological disorders. Currently in preclinical development. Competitors include large pharmaceutical companies with established MS drugs (e.g., Novartis, Biogen).

Market Dynamics

industry overview logo Industry Overview

The CNS therapeutics market is large and growing, driven by the increasing prevalence of mental health disorders and neurological diseases. There's a rising interest in novel approaches, including psychedelic-assisted therapies, although still in early stages.

Positioning

Pasithea is a relatively small player in the CNS therapeutics market, focusing on innovative treatments. Its competitive advantage lies in its focus on unique treatment mechanisms.

Total Addressable Market (TAM)

The total addressable market for CNS therapeutics is estimated in the hundreds of billions of dollars. Pasithea is targeting niche segments within this large market, such as specific neurological disorders, with the NET-100A PAS agonist.

Upturn SWOT Analysis

Strengths

  • Novel treatment approach (PAS agonism)
  • Experienced management team
  • Focus on underserved CNS markets

Weaknesses

  • Limited financial resources
  • Early stage of development (preclinical)
  • High regulatory risk

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new CNS indications
  • Positive clinical trial results

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Failure of clinical trials
  • Limited Funding

Competitors and Market Share

competitor logo Key Competitors

  • BIIB
  • NVS

Competitive Landscape

Pasithea faces intense competition from established pharmaceutical companies with larger R&D budgets and existing market presence. Its success depends on demonstrating superior efficacy and safety in clinical trials.

Growth Trajectory and Initiatives

Historical Growth: N/A, early stage company.

Future Projections: Future growth depends on the successful development and commercialization of its product candidates, especially NET-100A. Analyst projections are speculative at this point.

Recent Initiatives: Focusing on preclinical and clinical trial design and development for NET-100A.

Summary

Pasithea Therapeutics is a very early stage, high-risk, high-reward biotechnology company focused on innovative CNS therapies. Their success hinges on their ability to successfully progress NET-100A through clinical trials and secure funding. They should be aware of funding risks and intense competition from larger pharmaceuticals.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website, SEC filings, publicly available information, Analyst reports.

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on available data and is subject to change. Investing in early-stage biotechnology companies involves significant risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Pasithea Therapeutics Corp

Exchange NASDAQ
Headquaters Miami Beach, FL, United States
IPO Launch date 2021-09-15
CEO & Director Dr. Tiago Reis Marques M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.